Press Release

Recombinant Protein Market to Grow with a CAGR of 7.34% through 2028

Rising inclination towards biologics and biosimilars are expected to drive the Global Recombinant Protein Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Recombinant Protein Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Recombinant Protein Market stood at USD 2.19 Billion in 2022 and is anticipated to grow with a CAGR of 7.34% through 2028. Industry growth is expected to be propelled by the increasing occurrence of chronic ailments like hemophilia, granulomatous disease, and sclerosis. Additionally, the growing inclination towards biologics, as well as advancements in recombinant protein products, is other factors driving growth. In addition to the efforts made to build recombinant protein-based vaccinations, numerous players are putting up a great effort to develop medicines via rapid cycles of innovation to bring advances to patients more swiftly. The popularity of biopharmaceuticals has also been influenced by the need for safe, effective, and efficient medications. To revolutionize treatment efforts, many regions have created biobanks through cohort programs, which give researchers access to high-quality samples. This has raised interest in finding biomarkers for various disorders. For instance, the FDA authorized Ayvakit in August 2022 to treat advanced systemic mastocytosis, a rare blood disorder, which is anticipated to have a beneficial effect on the growth of the market in the years to come.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Recombinant Protein Market

 

The Global Recombinant Protein Market is segmented into Products, Application, and region.

Based on the Product, the antibody segment is anticipated to witness substantial market growth throughout the forecast period. The exponential growth of the global recombinant protein market is notably steered by the burgeoning demand for antibody products. Antibodies, with their pivotal role in targeted therapies and diagnostics, stand at the forefront of biopharmaceutical innovation. The increasing prevalence of chronic diseases, including cancer and autoimmune disorders, underscores the need for precise and efficacious treatments, propelling the demand for recombinant antibody-based therapeutics. The versatility of recombinant antibody technology allows for the engineering of monoclonal antibodies with enhanced specificity and reduced immunogenicity, addressing limitations associated with traditional therapeutic approaches. The development of novel antibodies for emerging infectious diseases and the expansion of personalized medicine further amplify the market's growth trajectory. Moreover, strategic collaborations and partnerships within the biopharmaceutical industry contribute to a robust pipeline of antibody products. These collaborations foster innovation, accelerate research and development efforts, and drive commercialization.

Based on the Application segment, the Therapeutic Use segment has been the dominant force in the market. The growth of the global recombinant protein market is strongly propelled by the expanding therapeutic applications of these biopharmaceuticals. Recombinant proteins serve as crucial components in the development of therapeutic interventions for a diverse range of medical conditions. From treating chronic diseases such as diabetes and cancer to addressing rare genetic disorders and autoimmune conditions, the therapeutic versatility of recombinant proteins positions them at the forefront of modern medicine. The trend towards personalized medicine further accentuates the significance of recombinant proteins, allowing for the customization of therapeutic solutions tailored to individual patient profiles. As advancements in biotechnology continue to unravel novel therapeutic targets, the demand for recombinant proteins is set to grow. Furthermore, the ongoing research and development efforts aimed at expanding the therapeutic repertoire of recombinant proteins, coupled with the regulatory support for these innovative treatments, create a conducive environment for market growth. 

Major companies operating in Global Recombinant Protein Market are:

  • Abbvie Inc.
  • Amgen Inc.
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Novavax Inc.
  • Pfizer Inc.

 Download Free Sample Report

Customers can also request 10% free customization on this report 

“The rising prevalence of chronic diseases, such as granulomatous disease, hemophilia, and sclerosis, is anticipated to drive industry growth. Furthermore, the rising preference for biologics as well as biosimilars, and enhanced recombinant protein products are some other factors contributing to the industry growth. In addition to the actions taken to develop recombinant protein-based vaccines, intense efforts are being taken by multiple players for therapeutics via accelerated cycles of innovation to bring breakthroughs to patients faster. Furthermore, the demand for effective, efficient, and safe drugs enhanced the popularity of biopharmaceuticals. Key players are investing in their R&D programs to increase research productivity and grow their offerings for revenue generation.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Recombinant Protein Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Hormone, Growth Factor, Antibody, Enzyme, Other), By Application (Research Application, Therapeutic Use, Biotechnology Industry), By Region, By Competition”, has evaluated the future growth potential of Global Recombinant Protein Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Recombinant Protein Market.

 


Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com


Relevant News